Relay Therapeutics (RLAY) is back in focus after releasing new Phase 1/2 ReDiscover trial data for zovegalisib plus fulvestrant in PI3Ka-mutated, HR+/HER2- metastatic breast cancer, supporting its selected Phase 3 dosing regimen.

The latest trial update comes after a sharp move in the stock, with a 1 day share price return of negative 5.14% and a 30 day share price return of negative 6.43%. However, a 1 year total shareholder return of 266.41% and a 5 year total shareholder return of negative 74.86% underline how momentum has shifted quickly over different periods.

If you are watching how oncology and biotech stories unfold, it can also be useful to see what else is moving in related areas, including 33 healthcare AI stocks

With the stock up sharply over 12 months yet still below its 5-year starting point and trading at a steep discount to average analyst targets, is Relay Therapeutics offering a fresh entry point or is future growth already captured in the price?

Preferred Price to Book of 3x, Is it justified?

Relay Therapeutics trades on a P/B ratio of 3x, which sits above the broader US biotechs industry average of 2.2x but below its closest peer group at 4.2x.

P/B compares a company’s market value to its net assets, which matters for a business like Relay that is currently loss making and not valued on earnings. A higher P/B can signal that investors are placing more weight on pipeline potential and future revenue than on the current balance sheet.

At 3x, the market is assigning Relay a richer valuation than the typical biotech name, yet still at a discount to peers that share similar characteristics. That gap to the peer average indicates that investors are recognizing the company’s growth forecasts while not pricing it at the upper end of sector expectations.

Result: Price-to-book of 3x (ABOUT RIGHT)

However, investors still face key risks, including future trial setbacks across Relay’s clinical programs and ongoing net losses, with the last reported net income at a loss of US$276.479 million.

Next Steps

Given the mix of optimism and concern running through this story, it makes sense to look at the details yourself and move quickly to shape your own view by weighing up the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If Relay has your attention, do not stop here. Broaden your watchlist with other potential opportunities that could complement or contrast this story.

• Target steady income by scanning companies built around robust payouts using the 12 dividend fortresses.
• Hunt for quality at a discount by focusing on stocks that look attractively priced with the 62 high quality undervalued stocks.
• Protect your downside by zeroing in on businesses that carry lower overall risk scores through the 64 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.